Publications by authors named "F Koiwa"
Article Synopsis
- - Malakoplakia is a rare inflammatory disease marked by specific cells and is particularly elusive when affecting the kidneys, as shown in a case involving a patient diagnosed in infancy.
- - After 17 years, the patient experienced kidney issues leading to a diagnosis of focal segmental glomerulosclerosis (FSGS), but typical malakoplakia markers were not found in kidney biopsy samples.
- - This case highlights that kidney damage from malakoplakia can evolve into FSGS and demonstrates how the disease can change over time, providing valuable insights into the long-term prognosis of renal parenchymal malakoplakia.
Introduction: Upacicalcet is a novel injectable calcimimetic. This phase 3 multicenter open-label study aimed to assess the long-term efficacy and safety of upacicalcet in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT).
Methods: Japanese HD patients with serum intact parathyroid hormone (iPTH) levels >240 pg/mL and corrected calcium (cCa) levels ≥8.
Introduction: The aim of the study was to explore the association between urate-lowering agents and reduced response to erythropoietin-stimulating agents in patients suffering from chronic kidney disease G5.
Methods: We conducted a cross-sectional, multicenter study in Japan between April and June 2013, enrolling patients aged 20 years or older with an estimated glomerular filtration rate of ≤15 mL/min/1.73 m2.
Background: Upacicalcet is a novel small-molecule calcimimetic agent developed for intravenous injection. Here, we evaluated the long-term efficacy and safety of upacicalcet treatment via intraindividual dose adjustment in haemodialysis patients with secondary hyperparathyroidism (SHPT).
Methods: A phase 2, multicentre, open-label, single-arm study was conducted.
Phosphate binders (PBs) generally have a high pill burden. Tenapanor selectively inhibits sodium/hydrogen exchanger isoform 3, reducing intestinal phosphate absorption. Tenapanor is a novel drug administered as a small tablet, twice daily.
View Article and Find Full Text PDF